FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1995586237> ?p ?o ?g. }

• W1995586237 endingPage "185" @default.
• W1995586237 startingPage "175" @default.
• W1995586237 abstract "Rheumatoid arthritis (RA) is an autoimmune disease characterized by abnormal prevalence of Th1, Th2, Th17, and regulatory (Treg) subsets. Some data suggest that these subsets are influenced by anti-RA agents. Follow-up studies monitoring T cell phenotype in response to therapy are limited. We investigated the alteration of CD4+ T cell subset distribution after the initiation of disease-modifying antirheumatic drug (DMARD) (with glucocorticosteroid (GCS) and methotrexate (MTX)) and anti-TNFα therapy. We enrolled 19 treatment naive (early) RA patients and initiated GCS (in a dose of 16 mg/day for 4 weeks; then 8 mg/day). MTX, 10 mg/week, was started at week 4. We also enrolled 32 RA patients unresponsive to DMARD and initiated anti-TNFα therapy: adalimumab (ADA), 40 mg/2 weeks, n = 12; etanercept (ETA), 50 mg/weeks, n = 12; or infliximab (IFX) on week 0, 2, and 6, 3 mg/kg bw, n = 8. Blood was taken before and 4 and 8 weeks after the initiation of therapy. Ten volunteers served as controls. The T cell phenotype was assessed with flow cytometry. In early RA, Th1, Th2, and Th17 prevalence was higher, while Treg prevalence was lower than normal. GCS alone decreased Th2 prevalence. GCS + MTX decreased Th17 prevalence. Immune phenotype in unresponsive RA before anti-TNF therapy was as in early RA. Four and 8 weeks after initiating anti-TNF therapy, Th1 prevalence was higher than baseline in ETA or IFX, while it was stable in ADA groups. Th2 prevalence was higher than normal in ADA or IFX, while normalized in ETA group. In each group, Treg prevalence increased, while Th17 prevalence was at the baseline. The proinflammatory immune phenotype is normalized only under GCS + MTX combination in early RA. Anti-TNFα therapy exhibit marked effects on all the cell populations investigated (except Th17); some slight differences in this action exist between ADA, ETA, and IFX therapy." @default.
• W1995586237 created "2016-06-24" @default.
• W1995586237 creator A5001023602 @default.
• W1995586237 creator A5015629505 @default.
• W1995586237 creator A5016585178 @default.
• W1995586237 creator A5023123752 @default.
• W1995586237 creator A5053078145 @default.
• W1995586237 creator A5069680386 @default.
• W1995586237 creator A5086573810 @default.
• W1995586237 date "2013-08-11" @default.
• W1995586237 modified "2023-10-18" @default.
• W1995586237 title "The impact of conventional DMARD and biological therapies on CD4+ cell subsets in rheumatoid arthritis: a follow-up study" @default.
• W1995586237 cites W1964215887 @default.
• W1995586237 cites W1967907511 @default.
• W1995586237 cites W1976173775 @default.
• W1995586237 cites W1978644929 @default.
• W1995586237 cites W1985680749 @default.
• W1995586237 cites W1990399188 @default.
• W1995586237 cites W1995288662 @default.
• W1995586237 cites W2009439458 @default.
• W1995586237 cites W2012633299 @default.
• W1995586237 cites W2020175179 @default.
• W1995586237 cites W2040375528 @default.
• W1995586237 cites W2041638840 @default.
• W1995586237 cites W2046838998 @default.
• W1995586237 cites W2052463028 @default.
• W1995586237 cites W2062264613 @default.
• W1995586237 cites W2064949253 @default.
• W1995586237 cites W2080241101 @default.
• W1995586237 cites W2080404460 @default.
• W1995586237 cites W2086721113 @default.
• W1995586237 cites W2093383759 @default.
• W1995586237 cites W2099271172 @default.
• W1995586237 cites W2117844639 @default.
• W1995586237 cites W2118268169 @default.
• W1995586237 cites W2119519960 @default.
• W1995586237 cites W2120989550 @default.
• W1995586237 cites W2123249923 @default.
• W1995586237 cites W2125478124 @default.
• W1995586237 cites W2137809958 @default.
• W1995586237 cites W2155630596 @default.
• W1995586237 cites W2156964052 @default.
• W1995586237 cites W2159174521 @default.
• W1995586237 cites W2159733538 @default.
• W1995586237 cites W2168628806 @default.
• W1995586237 cites W2171057871 @default.
• W1995586237 cites W4210968471 @default.
• W1995586237 cites W4211019157 @default.
• W1995586237 cites W4297789560 @default.
• W1995586237 doi "https://doi.org/10.1007/s10067-013-2352-x" @default.
• W1995586237 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23934385" @default.
• W1995586237 hasPublicationYear "2013" @default.
• W1995586237 type Work @default.
• W1995586237 sameAs 1995586237 @default.
• W1995586237 citedByCount "29" @default.
• W1995586237 countsByYear W19955862372013 @default.
• W1995586237 countsByYear W19955862372014 @default.
• W1995586237 countsByYear W19955862372015 @default.
• W1995586237 countsByYear W19955862372016 @default.
• W1995586237 countsByYear W19955862372017 @default.
• W1995586237 countsByYear W19955862372018 @default.
• W1995586237 countsByYear W19955862372019 @default.
• W1995586237 countsByYear W19955862372020 @default.
• W1995586237 countsByYear W19955862372021 @default.
• W1995586237 countsByYear W19955862372022 @default.
• W1995586237 countsByYear W19955862372023 @default.
• W1995586237 crossrefType "journal-article" @default.
• W1995586237 hasAuthorship W1995586237A5001023602 @default.
• W1995586237 hasAuthorship W1995586237A5015629505 @default.
• W1995586237 hasAuthorship W1995586237A5016585178 @default.
• W1995586237 hasAuthorship W1995586237A5023123752 @default.
• W1995586237 hasAuthorship W1995586237A5053078145 @default.
• W1995586237 hasAuthorship W1995586237A5069680386 @default.
• W1995586237 hasAuthorship W1995586237A5086573810 @default.
• W1995586237 hasBestOaLocation W19955862372 @default.
• W1995586237 hasConcept C126322002 @default.
• W1995586237 hasConcept C198451711 @default.
• W1995586237 hasConcept C203014093 @default.
• W1995586237 hasConcept C2777077863 @default.
• W1995586237 hasConcept C2777138892 @default.
• W1995586237 hasConcept C2777226972 @default.
• W1995586237 hasConcept C2777575956 @default.
• W1995586237 hasConcept C2779134260 @default.
• W1995586237 hasConcept C2780132546 @default.
• W1995586237 hasConcept C2781059491 @default.
• W1995586237 hasConcept C71924100 @default.
• W1995586237 hasConcept C8891405 @default.
• W1995586237 hasConcept C90924648 @default.
• W1995586237 hasConceptScore W1995586237C126322002 @default.
• W1995586237 hasConceptScore W1995586237C198451711 @default.
• W1995586237 hasConceptScore W1995586237C203014093 @default.
• W1995586237 hasConceptScore W1995586237C2777077863 @default.
• W1995586237 hasConceptScore W1995586237C2777138892 @default.
• W1995586237 hasConceptScore W1995586237C2777226972 @default.
• W1995586237 hasConceptScore W1995586237C2777575956 @default.
• W1995586237 hasConceptScore W1995586237C2779134260 @default.
• W1995586237 hasConceptScore W1995586237C2780132546 @default.
• W1995586237 hasConceptScore W1995586237C2781059491 @default.

• next